



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

| SERIAL NUMBER | FILING DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NO. |
|---------------|-------------|-----------------------|---------------------|
| 08/231 565 | 04/22/94 | KAWAKAMI | 20264124 |

WILLIAM S. FEILER, ESQ.
MORGAN & FINNEGAN
345 PARK AVENUE
NEW YORK, NEW YORK 10154

18N1/0929
RECEIVED
DOCKET DEPT.

OCT 05 1995

MORGAN & FINNEGAN

| | |
|--------------------|--------------|
| CAPUTA, A EXAMINER | |
| ART UNIT | PAPER NUMBER |
| 1812 | |

DATE MAILED:

09/29/95

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner Caputa, Art Unit 1813, whose telephone number is (703) 308-3995.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Missing parts
CASE 7026-4124 CMG

DUE DATE October 29, 1995 ✓

STATUTORY DATE February 29, 1996 ✓

PTOL-90 (Rev. 6/84)

BY KB

CHRISTINE M. NUCKER
SUPERVISORY PATENT EXAMINER
GROUP 180

2-APPLICANTS COPY

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/231,565DATE: 09/28/95
TIME: 13:30:21

INPUT SET: S6404.raw

This Raw Listing contains the General
Information Section and those Sequences
containing ERRORS.

SEQUENCE LISTING

1
2
3 (1) General Information:
4
5 (i) APPLICANTS: KAWAKAMI, YUTAKA; ROSENBERG,
6 STEVEN A.
7
8 (ii) TITLE OF INVENTION: MELANOMA ANTIGENS AND
9 THEIR USE IN DIAGNOSTIC AND THERAPEUTIC
10 METHODS
11
12 (iii) NUMBER OF SEQUENCES: 45
13
14 (iv) CORRESPONDENCE ADDRESS:
15 (A) ADDRESSEE: MORGAN & FINNEGAN
16 (B) STREET: 345 PARK AVENUE
17 (C) CITY: NEW YORK
18 (D) STATE: NEW YORK
19 (E) COUNTRY: USA
20 (F) ZIP: 10154
21
22 (v) COMPUTER READABLE FORM:
23 (A) MEDIUM TYPE: FLOPPY DISK
24 (B) COMPUTER: IBM PC COMPATIBLE
25 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
26 (D) SOFTWARE: WORDPERFECT 5.1
27
28 (vi) CURRENT APPLICATION DATA:
29 (A) APPLICATION NUMBER: 08/231,565
30 (B) FILING DATE: 22-APR-1994
31 (C) CLASSIFICATION:
32
33 (viii) ATTORNEY/AGENT INFORMATION:
34 (A) NAME: CAROL M. GRUPPI
35 (B) REGISTRATION NUMBER: 37,341
36 (C) REFERENCE/DOCKET NUMBER: 2026-4124
37
38 (ix) TELECOMMUNICATION INFORMATION:
39 (A) TELEPHONE: (212) 758-4800
40 (B) TELEFAX: (212) 751-6849
41 (C) TELEX: 421792
42

ERRORED SEQUENCES FOLLOW:

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/231,565DATE: 09/28/95
TIME: 13:30:24

INPUT SET: S6404.raw

980 (2) INFORMATION FOR SEQ ID NO:32:

981

982 (i) SEQUENCE CHARACTERISTICS: 7 or 21?

-->

983 (A) LENGTH: 11

984 (B) TYPE: amino acid

985 (C) STRANDEDNESS: Unknown

986 (D) TOPOLOGY: Unknown

987

988 (ii) MOLECULE TYPE: Protein

989

990 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

991

992 Gln Leu Val Pro Gly Ile Leu Leu Thr Pro Pro Gln

993 1 5 10

994 Trp Ala Ala Gly Leu Ser Thr Leu Ile ← 21 shown

995 15 20

996

1190 (2) INFORMATION FOR SEQ ID NO:44:

1191

1192 (i) SEQUENCE CHARACTERISTICS:

-->

1193 (A) LENGTH: 14 15 shown.

1194 (B) TYPE: NUCLEOTIDE

1195 (C) STRANDEDNESS: DOUBLE

1196 (D) TOPOLOGY: UNKNOWN

1197

1198

1199

1200

1201

1202

1203

1204 (ii) MOLECULE TYPE: cDNA

1205

1206 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

1207

-->

1208 GGTCGCGATTG GTAA 14?

1209

1210

↑
group of 11, not 10. IS there an extra?

PAGE: 1

SEQUENCE VERIFICATION REPORT
PATENT APPLICATION US/08/231,565

DATE: 09/28/95
TIME: 13:30:28

INPUT SET: S6404.raw

| Line | Error | Original Text |
|------|--|------------------|
| 983 | Entered (11) and Calc. Seq. Length (21) differ | (A) LENGTH: 11 |
| 1193 | Entered (14) and Calc. Seq. Length (15) differ | (A) LENGTH: 14 |
| 1208 | # of Sequences for line conflicts w/ running total | GGTCGCGATTG GTAA |